SectorChemical and pharmaceutical
Established Date13/02/2003
Listing Date23/09/2016
ExchangeNASDAQ Stock Exchange
Full-time Employees90
Fiscal Year Ends31/12
Security TypeCommon stock
Office addressEPFL INNOVATION PARK, Building B, 1015 Lausanne, Switzerland
BusinessDiscovers and develops medicines and diagnostics for neurodegenerative diseases.
IntroductionAC Immune SA was first incorporated in Basel on February 13, 2003 as a limited liability company and was later incorporated in June 2021 under the laws of the State of Delaware. AC Immune SA is a leading clinical-stage biopharmaceutical company dedicated to pioneering the field of precision medicine in neurodegenerative diseases. Leveraging two proprietary technology platforms, Supra Antigen and Morphomer, the company has built a comprehensive pipeline of first-in-class or best-in-class drug candidates covering multiple treatment models for both existing and emerging neurodegenerative diseases. The company is currently advancing 16 therapeutic and diagnostic programs, seven of which are undergoing clinical trials for five different types of misfolded pathological proteins associated with Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases.
